240 related articles for article (PubMed ID: 26434717)
21. α-Synuclein is a Novel Microtubule Dynamase.
Cartelli D; Aliverti A; Barbiroli A; Santambrogio C; Ragg EM; Casagrande FV; Cantele F; Beltramone S; Marangon J; De Gregorio C; Pandini V; Emanuele M; Chieregatti E; Pieraccini S; Holmqvist S; Bubacco L; Roybon L; Pezzoli G; Grandori R; Arnal I; Cappelletti G
Sci Rep; 2016 Sep; 6():33289. PubMed ID: 27628239
[TBL] [Abstract][Full Text] [Related]
22. Identifying the Pathological Domain of Alpha- Synuclein as a Therapeutic for Parkinson's Disease.
Shen N; Song G; Yang H; Lin X; Brown B; Hong Y; Cai J; Cao C
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31083520
[TBL] [Abstract][Full Text] [Related]
23. γ-Synuclein: seeding of α-synuclein aggregation and transmission between cells.
Surgucheva I; Sharov VS; Surguchov A
Biochemistry; 2012 Jun; 51(23):4743-54. PubMed ID: 22620680
[TBL] [Abstract][Full Text] [Related]
24. Epitope region identification challenges of intrinsically disordered proteins in neurodegenerative diseases: Secondary structure dependence of α-synuclein on simulation techniques and force field parameters.
Mandaci SY; Caliskan M; Sariaslan MF; Uversky VN; Coskuner-Weber O
Chem Biol Drug Des; 2020 Jul; 96(1):659-667. PubMed ID: 31903719
[TBL] [Abstract][Full Text] [Related]
25. Fluorescence studies suggest a role for alpha-synuclein in the phosphatidylinositol lipid signaling pathway.
Narayanan V; Guo Y; Scarlata S
Biochemistry; 2005 Jan; 44(2):462-70. PubMed ID: 15641770
[TBL] [Abstract][Full Text] [Related]
26. Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy.
Paleologou KE; Irvine GB; El-Agnaf OM
Biochem Soc Trans; 2005 Nov; 33(Pt 5):1106-10. PubMed ID: 16246056
[TBL] [Abstract][Full Text] [Related]
27. Haploinsufficiency of cathepsin D leads to lysosomal dysfunction and promotes cell-to-cell transmission of α-synuclein aggregates.
Bae EJ; Yang NY; Lee C; Kim S; Lee HJ; Lee SJ
Cell Death Dis; 2015 Oct; 6(10):e1901. PubMed ID: 26448324
[TBL] [Abstract][Full Text] [Related]
28. Contact between the β1 and β2 Segments of α-Synuclein that Inhibits Amyloid Formation.
Shaykhalishahi H; Gauhar A; Wördehoff MM; Grüning CS; Klein AN; Bannach O; Stoldt M; Willbold D; Härd T; Hoyer W
Angew Chem Int Ed Engl; 2015 Jul; 54(30):8837-40. PubMed ID: 26119103
[TBL] [Abstract][Full Text] [Related]
29. Controlling the mass action of alpha-synuclein in Parkinson's disease.
Kim C; Lee SJ
J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
[TBL] [Abstract][Full Text] [Related]
30. Pressure-temperature folding landscape in proteins involved in neurodegenerative diseases and cancer.
Cordeiro Y; Foguel D; Silva JL
Biophys Chem; 2013 Dec; 183():9-18. PubMed ID: 23849959
[TBL] [Abstract][Full Text] [Related]
31. Interactions between metals and alpha-synuclein--function or artefact?
Brown DR
FEBS J; 2007 Aug; 274(15):3766-74. PubMed ID: 17617226
[TBL] [Abstract][Full Text] [Related]
32. DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function.
Plotegher N; Berti G; Ferrari E; Tessari I; Zanetti M; Lunelli L; Greggio E; Bisaglia M; Veronesi M; Girotto S; Dalla Serra M; Perego C; Casella L; Bubacco L
Sci Rep; 2017 Jan; 7():40699. PubMed ID: 28084443
[TBL] [Abstract][Full Text] [Related]
33. Oxidative stress-induced posttranslational modifications of alpha-synuclein: specific modification of alpha-synuclein by 4-hydroxy-2-nonenal increases dopaminergic toxicity.
Xiang W; Schlachetzki JC; Helling S; Bussmann JC; Berlinghof M; Schäffer TE; Marcus K; Winkler J; Klucken J; Becker CM
Mol Cell Neurosci; 2013 May; 54():71-83. PubMed ID: 23369945
[TBL] [Abstract][Full Text] [Related]
34. Monomeric and fibrillar α-synuclein exert opposite effects on the catalytic cycle that promotes the proliferation of Aβ42 aggregates.
Chia S; Flagmeier P; Habchi J; Lattanzi V; Linse S; Dobson CM; Knowles TPJ; Vendruscolo M
Proc Natl Acad Sci U S A; 2017 Jul; 114(30):8005-8010. PubMed ID: 28698377
[TBL] [Abstract][Full Text] [Related]
35. Dopamine-induced conformational changes in alpha-synuclein.
Outeiro TF; Klucken J; Bercury K; Tetzlaff J; Putcha P; Oliveira LM; Quintas A; McLean PJ; Hyman BT
PLoS One; 2009 Sep; 4(9):e6906. PubMed ID: 19730729
[TBL] [Abstract][Full Text] [Related]
36. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
Chaari A; Hoarau-Véchot J; Ladjimi M
Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
[TBL] [Abstract][Full Text] [Related]
37. Curcumin Pyrazole and its derivative (N-(3-Nitrophenylpyrazole) Curcumin inhibit aggregation, disrupt fibrils and modulate toxicity of Wild type and Mutant α-Synuclein.
Ahsan N; Mishra S; Jain MK; Surolia A; Gupta S
Sci Rep; 2015 May; 5():9862. PubMed ID: 25985292
[TBL] [Abstract][Full Text] [Related]
38. Differential aggregation properties of alpha-synuclein isoforms.
Bungeroth M; Appenzeller S; Regulin A; Völker W; Lorenzen I; Grötzinger J; Pendziwiat M; Kuhlenbäumer G
Neurobiol Aging; 2014 Aug; 35(8):1913-9. PubMed ID: 24629672
[TBL] [Abstract][Full Text] [Related]
39. Enzymatic O-GlcNAcylation of α-synuclein reduces aggregation and increases SDS-resistant soluble oligomers.
Zhang J; Lei H; Chen Y; Ma YT; Jiang F; Tan J; Zhang Y; Li JD
Neurosci Lett; 2017 Aug; 655():90-94. PubMed ID: 28673834
[TBL] [Abstract][Full Text] [Related]
40. Lipid peroxidation product 4-hydroxy-2-nonenal promotes seeding-capable oligomer formation and cell-to-cell transfer of α-synuclein.
Bae EJ; Ho DH; Park E; Jung JW; Cho K; Hong JH; Lee HJ; Kim KP; Lee SJ
Antioxid Redox Signal; 2013 Mar; 18(7):770-83. PubMed ID: 22867050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
